Ma Ke, Jiang Wei, Wang Yun-Xia, Wang Lin, Lv Yan, Liu Jin-Feng, Liu Rong-Guo, Liu Hui, Xiao Li-Zu, Du Dong-Ping, Lu Li-Juan, Yang Xiao-Qiu, Xia Ling-Jie, Huang Dong, Fu Zhi-Jian, Peng Bao-Gan, Liu Yan-Qing
Department of Algology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China.
Department of Anesthesiology, Third Medical Center of People's Liberation Army General Hospital, Beijing 100039, China.
World J Clin Cases. 2021 Mar 26;9(9):2110-2122. doi: 10.12998/wjcc.v9.i9.2110.
Chronic pain lasting more than 3 mo, or even several years can lead to disability. Treating chronic pain safely and effectively is a critical challenge faced by clinicians. Because administration of analgesics through oral, intravenous or intramuscular routes is not satisfactory, research toward percutaneous delivery has gained interest. The transdermal patch is one such percutaneous delivery system that can deliver drugs through the skin and capillaries at a certain rate to achieve a systemic or local therapeutic effect in the affected area. It has many advantages including ease of administration and hepatic first pass metabolism avoidance as well as controlling drug delivery, which reduces the dose frequency and side effects. If not required, then the patch can be removed from the skin immediately. The scopolamine patch was the first transdermal patch to be approved for the treatment of motion sickness by the Food and Drug Administration in 1979. From then on, the transdermal patch has been widely used to treat many diseases. To date, no guidelines or consensus are available on the use of analgesic drugs through transdermal delivery. The pain branch of the Chinese Medical Association, after meeting and discussing with experts and based on clinical evidence, developed a consensus for promoting and regulating standard use of transdermal patches containing analgesic drugs.
持续超过3个月甚至数年的慢性疼痛会导致残疾。安全有效地治疗慢性疼痛是临床医生面临的一项严峻挑战。由于通过口服、静脉或肌肉途径给药并不理想，经皮给药的研究受到了关注。透皮贴剂就是这样一种经皮给药系统，它可以以一定速率通过皮肤和毛细血管输送药物，从而在受影响区域实现全身或局部治疗效果。它具有许多优点，包括给药方便、避免肝脏首过代谢以及控制药物输送，这减少了给药频率和副作用。如果不需要，贴剂可以立即从皮肤上取下。东莨菪碱贴剂是1979年首个被美国食品药品监督管理局批准用于治疗晕动病的透皮贴剂。从那时起，透皮贴剂被广泛用于治疗多种疾病。迄今为止，尚无关于通过透皮给药使用镇痛药的指南或共识。中华医学会疼痛分会在与专家会面并讨论后，基于临床证据，制定了一份关于促进和规范含镇痛药透皮贴剂标准使用的共识。
